Abstract
Percutaneous mitral valve repair is emerging as a reasonable alternative especially in those with an unfavorable surgical risk profile in the repair of mitral regurgitation. At this time, our understanding of the effects of underlying renal dysfunction on outcomes with percutaneous mitral valve repair and the effects of this procedure itself on renal function is evolving, as more data emerges in this field. The current evidence suggests that the correction of mitral regurgitation via percutaneous mitral valve repair is associated with some degree of improvement in cardiac function, hemodynamics and renal function. The improvement in renal function was more significant for those with greater renal dysfunction at baseline. The presence of Chronic Kidney Disease (CKD) in turn has been associated with poor long-term outcomes including increased mortality and hospitalization among patients who undergo percutaneous mitral valve repair. This was true regardless of the degree of improvement in GFR post repair advanced CKD. The adverse impact of CKD on long-term outcomes was consistent across all studies and was more prominent in those with GFR<30 mL/min/1.73 m². It is clear that from these contrasting evidences of improved renal function post mitral valve repair but poor long-term outcomes including increased mortality in patients with CKD, that proper patient selection for percutaneous mitral valve repair is key. There is a need to have better-standardized criteria for patients who should qualify to have percutaneous mitral valve replacement with Mitraclip. In this new era of percutaneous mitral valve repair, much work needs to be done to optimize long-term patient outcomes.
Keywords: Percutaneous mitral repair, renal function, review, mitraclip, chronic kidney disease, patient outcomes.
Graphical Abstract
[1]
Kainuma S, Taniguchi K, Daimon T, et al. Mitral valve repair for medically refractory functional mitral regurgitation in patients with end-stage renal disease and advanced heart failure. Circulation 2012; 126(11)(Suppl. 1): S205-13.
[2]
Wan B, Rahnavardi M, Tian DH, et al. A meta-analysis of MitraClip system versus surgery for treatment of severe mitral regurgitation. Ann Cardiothorac Surg 2013; 2(6): 683.
[3]
Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364(15): 1395-406.
[4]
Sürder D, Pedrazzini G, Gaemperli O, et al. Predictors for efficacy of percutaneous mitral valve repair using the MitraClip system: The results of the MitraSwiss registry. Heart 2013; 99(14): 1034-40.
[5]
Toggweiler S, Zuber M, Sürder D, et al. Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: Durability of the procedure and predictors of outcome. Open Heart 2014; 1(1): e000056.
[6]
Ohno Y, Attizzani GF, Capodanno D, et al. Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry. Eur Heart J Cardiovasc Imaging 2014; 15(11): 1246-55.
[7]
Paranskaya L, D’ancona G, Bozdag‐Turan I, et al. Residual mitral valve regurgitation after percutaneous mitral valve repair with the mitraclip® system is a risk factor for adverse one‐year outcome. Catheter Cardiovasc Interv 2013; 81(4): 609-17.
[8]
Kahn MR, Robbins MJ, Kim MC, Fuster V. Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol 2013; 10(5): 261.
[9]
Gaasch WH, Zile MR. Left ventricular function after surgical correction of chronic mitral regurgitation. Eur Heart J 1991; 12(Suppl. B): 48-51.
[10]
Shah PM, Adelman AG, Wigle ED, et al. The natural and unnatural history of hypertrophic obstructive cardiomyopathy: A multicenter study. Circ Res 1974; 35(2): II-179.
[11]
Zile MR, Gaasch WH, Levine HJ. Left ventricular stress-dimension-shortening relations before and after correction of chronic aortic and mitral regurgitation. Am J Cardiol 1985; 56(1): 99-105.
[12]
Corin WJ, Monrad ES, Murakami T, Nonogi H, Hess OM, Krayenbuehl HP. The relationship of afterload to ejection performance in chronic mitral regurgitation. Circulation 1987; 76(1): 59-67.
[13]
Rassaf T, Balzer J, Rammos C, et al. Influence of percutaneous mitral valve repair using the MitraClip® system on renal function in patients with severe mitral regurgitation. Catheter Cardiovasc Interv 2015; 85(5): 899-903.
[14]
Parfrey PS, Harriett JD, Griffiths SM, et al. The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 1990; 55(2): 114-20.
[15]
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 2014; 148(1): e1-e32.
[16]
Vahanian A. Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology: ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230-68.
[17]
Feldman T, Wasserman HS, Herrmann HC, et al. Percutaneous mitral valve repair using the edge-to-edge technique: Six-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol 2005; 46(11): 2134-40.
[18]
Wang A, Sangli C, Lim S, et al. Evaluation of renal function before and after percutaneous mitral valve repair. Circ Cardiovasc Interv 2015; 8(1): e001349.
[19]
Kaneko H, Neuss M, Schau T, Weissenborn J, Butter C. Interaction between renal function and percutaneous edge-to-edge mitral valve repair using MitraClip. J Cardiol 2017; 69(2): 476-82.
[20]
Kubo S, Nakamura M, Shiota T, et al. Impact of forward stroke volume response on clinical and structural outcomes after percutaneous mitral valve repair with mitraclip. Circ Cardiovasc Interv 2017; 10(7): e004909.
[21]
Braunwald E. Mitral regurgitation: physiologic, clinical and surgical considerations. N Engl J Med 1969; 281(8): 425-33.
[22]
Damman K, Navis G, Smilde TD, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007; 9(9): 872-8.
[23]
Biner S, Siegel RJ, Feldman T, et al. Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation. Eur J Heart Fail 2012; 14(8): 939-45.
[24]
Siegel RJ, Biner S, Rafique AM, et al. The acute hemodynamic effects of MitraClip therapy. J Am Coll Cardiol 2011; 57(16): 1658-65.
[25]
Hoar PF, Mookerjee A, Stone JG, Wicks AE, Malm JR, Mirsky MB. Acute hemodynamic alterations after mitral valve replacement with the glutaraldehyde-treated porcine heterograft prosthesis. Ann Thorac Surg 1980; 29(5): 434-9.
[26]
Landoni G, Zangrillo A, Franco A, et al. Long-term outcome of patients who require renal replacement therapy after cardiac surgery. Eur J Anaesthesiol 2006; 23(1): 17-22.
[27]
Tang P, Onaitis M, Desai B, et al. Minithoracotomy versus sternotomy for mitral surgery in patients with chronic renal impairment: a propensity-matched study. Innovations (Phila) 2013; 8(5): 325-31.
[28]
Loef BG, Epema AH, Smilde TD, et al. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc Nephrol 2005; 16(1): 195-200.
[29]
Foster E, Kwan D, Feldman T, et al. Percutaneous mitral valve repair in the initial EVEREST cohort: Evidence of reverse left ventricular remodeling. Circ Cardiovasc Imaging 2013; 6(4): 522-30.
[30]
Grayburn PA, Foster E, Sangli C, et al. The relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after mitraclip® therapy. Circulation 2013; 128(15): 1667-74.
[31]
Suri RM, Schaff HV, Dearani JA, et al. Recovery of left ventricular function after surgical correction of mitral regurgitation caused by leaflet prolapse. J Thorac Cardiovasc Surg 2009; 137(5): 1071-6.
[32]
Husain-Syed F, McCullough PA, Birk HW, et al. Cardio-pulmonary-renal interactions. J Am Coll Cardiol 2015; 65(22): 2433-48.
[33]
Vitarelli A, Mangieri E, Capotosto L, et al. Assessment of biventricular function by three-dimensional speckle-tracking echocardiography in secondary mitral regurgitation after repair with the MitraClip system. J Am Soc Echocardiogr 2015; 28(9): 1070-82.
[34]
Moesgaard SG, Klostergaard C, Zois NE, et al. Flow‐mediated vasodilation measurements in Cavalier King Charles Spaniels with increasing severity of myxomatous mitral valve disease. J Vet Intern Med 2012; 26(1): 61-8.
[35]
Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87(10): 840-4.
[36]
Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 2002; 62(5): 1539-49.
[37]
Rammos C, Zeus T, Balzer J, et al. Percutaneous mitral valve repair in mitral regurgitation reduces cell-free hemoglobin and improves endothelial function. PLoS One 2016; 11(3): e0151203.
[38]
Körber MI, Scherner M, Kuhr K, et al. Acute kidney injury following percutaneous edge-to-edge vs. minimally invasive surgical mitral valve repair: Incidence, predictors and prognostic value. EuroIntervention 2018; 13(14): 1645-51.
[39]
Chang CH, Lee CC, Chen SW, et al. Predicting acute kidney injury following mitral valve repair. Int J Med Sci 2016; 13(1): 19.
[40]
Ram P, Mezue K, Pressman G, Rangaswami J. Acute kidney injury post–transcatheter aortic valve replacement. Clin Cardiol 2017; 40(12): 1357-62.
[41]
Spieker M, Hellhammer K, Katsianos S, et al. Effect of acute kidney injury following percutaneous mitral valve repair on outcome. Am J Cardiol 2018; 122(2): 316-22.
[42]
Kooiman J, Seth M, Nallamothu BK, Heung M, Humes D, Gurm HS. Association between acute kidney injury and in-hospital mortality in patients undergoing percutaneous coronary interventions. Circ Cardiovasc Interv 2015; 8(6): e002212.
[43]
Lio A, Miceli A, Varone E, et al. Mitral valve repair versus replacement in patients with ischaemic mitral regurgitation and depressed ejection fraction: Risk factors for early and mid-term mortality. Interact Cardiovasc Thorac Surg 2014; 19(1): 64-9.
[44]
Udesh R, Mehta A, Gleason TG, Wechsler L, Thirumala PD. Perioperative strokes and early outcomes in mitral valve surgery: a nationwide analysis. J Cardiothorac Vasc Anesth 2017; 31(2): 529-36.
[45]
Ledwoch J, Bertog S, Wunderlich N, et al. Predictors for prolonged hospital stay after transcatheter mitral valve repair with the MitraClip®. Catheter Cardiovasc Interv 2014; 84(4): 599-605.
[46]
Damman K, Valente MA, Voors AA, O’connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J 2013; 35(7): 455-69.
[47]
Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL. The cardiorenal syndrome in heart failure. Prog Cardiovasc Dis 2011; 54(2): 144-53.
[48]
Cooper WA, O’brien SM, Thourani VH, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: Results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 2006; 113(8): 1063-70.
[49]
Gupta T, Goel K, Kolte D, et al. Association of chronic kidney disease with in-hospital outcomes of transcatheter aortic valve replacement. JACC Cardiovasc Interv 2017; 10(20): 2050-60.
[50]
Lio A, Miceli A, Varone E, et al. Mitral valve repair versus replacement in patients with ischaemic mitral regurgitation and depressed ejection fraction: Risk factors for early and mid-term mortality. Interact Cardiovasc Thorac Surg 2014; 19(1): 64-9.
[51]
Udesh R, Mehta A, Gleason TG, Wechsler L, Thirumala PD. Perioperative strokes and early outcomes in mitral valve surgery: A nationwide analysis. J Cardiothorac Vasc Anesth 2017; 31(2): 529-36.
[52]
Ledwoch J, Bertog S, Wunderlich N, et al. Predictors for prolonged hospital stay after transcatheter mitral valve repair with the MitraClip®. Catheter Cardiovasc Interv 2014; 84(4): 599-605.
[53]
Estévez-Loureiro R, Settergren M, Pighi M, et al. Effect of advanced chronic kidney disease in clinical and echocardiographic outcomes of patients treated with MitraClip system. Int J Cardiol 2015; 198: 75-80.
[54]
Shah B, Vemulapalli S, Manandhar P, et al. Outcomes after transcatheter mitral valve repair in patients with chronic kidney disease: An analysis of 5,241 patients in the United States. J Am Coll Cardiol 2018; 71(11): A1980.
[55]
Dumonteil N, Van Der Boon RM, Tchetche D, et al. Impact of preoperative chronic kidney disease on short-and long-term outcomes after transcatheter aortic valve implantation: A Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy. Am Heart J 2013; 165(5): 752-60.
Article Metrics
55
2
1
1